199 related articles for article (PubMed ID: 33512782)
1. The effect of three major co-morbidities on quality of life and outcome of patients with heart failure with reduced ejection fraction.
Benes J; Kotrc M; Jarolim P; Hoskova L; Hegarova M; Dorazilova Z; Podzimkova M; Binova J; Lukasova M; Malek I; Franekova J; Jabor A; Kautzner J; Melenovsky V
ESC Heart Fail; 2021 Apr; 8(2):1417-1426. PubMed ID: 33512782
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study.
Iorio A; Senni M; Barbati G; Greene SJ; Poli S; Zambon E; Di Nora C; Cioffi G; Tarantini L; Gavazzi A; Sinagra G; Di Lenarda A
Eur J Heart Fail; 2018 Sep; 20(9):1257-1266. PubMed ID: 29917301
[TBL] [Abstract][Full Text] [Related]
3. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
Wolsk E; Claggett B; Køber L; Pocock S; Yusuf S; Swedberg K; McMurray JJV; Granger CB; Pfeffer MA; Solomon SD
Eur J Heart Fail; 2018 Mar; 20(3):504-510. PubMed ID: 29193462
[TBL] [Abstract][Full Text] [Related]
4. The associations among co-morbidity, cardiac geometries and mechanics in hospitalized heart failure with or without preserved ejection fraction.
Lo CI; Lai YH; Chang SN; Kuo JY; Hsieh YC; Bulwer BE; Hung CL; Yeh HI
Clin Exp Hypertens; 2017; 39(5):473-480. PubMed ID: 28569600
[TBL] [Abstract][Full Text] [Related]
5. Exercise training and high-sensitivity cardiac troponin-I in patients with heart failure with reduced ejection fraction.
Riveland E; Valborgland T; Ushakova A; Skadberg Ø; Karlsen T; Hole T; Støylen A; Dalen H; Videm V; Koppen E; Linke A; Delagardelle C; Van Craenenbroeck EM; Beckers P; Prescott E; Halle M; Omland T; Ellingsen Ø; Larsen AI;
ESC Heart Fail; 2024 Apr; 11(2):1121-1132. PubMed ID: 38268237
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction.
Nolte K; Herrmann-Lingen C; Platschek L; Holzendorf V; Pilz S; Tomaschitz A; Düngen HD; Angermann CE; Hasenfuß G; Pieske B; Wachter R; Edelmann F
ESC Heart Fail; 2019 Apr; 6(2):262-270. PubMed ID: 30784226
[TBL] [Abstract][Full Text] [Related]
7. Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction.
Lund LH; Donal E; Oger E; Hage C; Persson H; Haugen-Löfman I; Ennezat PV; Sportouch-Dukhan C; Drouet E; Daubert JC; Linde C;
Eur J Heart Fail; 2014 Sep; 16(9):992-1001. PubMed ID: 25046483
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, clinical characteristics, quality of life, and prognosis of patients with congestive heart failure and isolated left ventricular diastolic dysfunction.
Badano LP; Albanese MC; De Biaggio P; Rozbowsky P; Miani D; Fresco C; Fioretti PM
J Am Soc Echocardiogr; 2004 Mar; 17(3):253-61. PubMed ID: 14981424
[TBL] [Abstract][Full Text] [Related]
9. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.
Brunner-La Rocca HP; Eurlings L; Richards AM; Januzzi JL; Pfisterer ME; Dahlström U; Pinto YM; Karlström P; Erntell H; Berger R; Persson H; O'Connor CM; Moertl D; Gaggin HK; Frampton CM; Nicholls MG; Troughton RW
Eur J Heart Fail; 2015 Dec; 17(12):1252-61. PubMed ID: 26419999
[TBL] [Abstract][Full Text] [Related]
10. Heart failure ejection fraction class conversions: impact of biomarkers, co-morbidities, and pharmacotherapy.
Lorenzo CJ; Conte JI; Villasmil RJ; Abdelal QK; Pierce D; Wiese-Rometsch W; Garcia-Fernandez JA
ESC Heart Fail; 2022 Aug; 9(4):2538-2547. PubMed ID: 35570322
[TBL] [Abstract][Full Text] [Related]
11. Combination of ST2 and B-type natriuretic peptide in diabetic patients with acute heart failure: relation with ventricular stiffness and outcome.
Ruocco G; Evangelista I; Franci B; Lucani B; Martini S; Nuti R; Palazzuoli A
J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):81-90. PubMed ID: 30540645
[TBL] [Abstract][Full Text] [Related]
12. Functional Status, Pulmonary Artery Pressure, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.
Dalos D; Mascherbauer J; Zotter-Tufaro C; Duca F; Kammerlander AA; Aschauer S; Bonderman D
J Am Coll Cardiol; 2016 Jul; 68(2):189-99. PubMed ID: 27386773
[TBL] [Abstract][Full Text] [Related]
13. Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.
Fu EL; Uijl A; Dekker FW; Lund LH; Savarese G; Carrero JJ
Circ Heart Fail; 2020 Nov; 13(11):e007180. PubMed ID: 33070637
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
[TBL] [Abstract][Full Text] [Related]
15. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
Trippel TD; Van Linthout S; Westermann D; Lindhorst R; Sandek A; Ernst S; Bobenko A; Kasner M; Spillmann F; González A; López B; Ravassa S; Pieske B; Paulus WJ; Díez J; Edelmann F; Tschöpe C
Eur J Heart Fail; 2018 Mar; 20(3):460-470. PubMed ID: 28891228
[TBL] [Abstract][Full Text] [Related]
16. Effect of disease-modifying agents and their association with mortality in multi-morbid patients with heart failure with reduced ejection fraction.
Straw S; McGinlay M; Relton SD; Koshy AO; Gierula J; Paton MF; Drozd M; Lowry JE; Cole C; Cubbon RM; Witte KK; Kearney MT
ESC Heart Fail; 2020 Dec; 7(6):3859-3870. PubMed ID: 32924331
[TBL] [Abstract][Full Text] [Related]
17. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
[No Abstract] [Full Text] [Related]
18. Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40.
Zhao M; Xin Y; Li J; Cao X; Liu X
Medicine (Baltimore); 2019 Sep; 98(39):e17296. PubMed ID: 31574852
[TBL] [Abstract][Full Text] [Related]
19. The Role of GDF-15 in Heart Failure Patients With Chronic Kidney Disease.
Benes J; Kotrc M; Wohlfahrt P; Conrad MJ; Franekova J; Jabor A; Lupinek P; Kautzner J; Melenovsky V; Jarolim P
Can J Cardiol; 2019 Apr; 35(4):462-470. PubMed ID: 30935637
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Predictors of Heart Failure With Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of Preclinical Left Ventricular Diastolic Dysfunction.
Zhang L; Liebelt JJ; Madan N; Shan J; Taub CC
Am J Cardiol; 2017 Jun; 119(11):1815-1820. PubMed ID: 28450040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
